| Ticker Symbol: |
PFE - USA Markets |
| Stock Last Traded Price: |
$23.24 |
| Stock Last Traded At: |
12/21/2007 4:00pm |
| Change: |
+0.02 |
| Opened At: |
$23.37 |
| Day Range: |
$23.43 - $23.13 |
| Volume: |
61641440
|
| Page Last Updated: |
12/21/2007 - 4:00pm |
New Page 1
- This Week's Barron's Roundup (at TheStreet.com)
- Is Your Portfolio Safe? (at Motley Fool)
- [$$] Power Players (at Barron's Online)
- [$$] Time to Let the Dogs Out (at Barron's Online)
- UPDATE - Pfizer says US FDA wants more data on antibiotic (at Reuters)
- Flamel Wheeling and Dealing (at Motley Fool)
- Trial and Error for Array BioPharma (at Motley Fool)
- FDA Asks for More Data on Pfizer Drug (AP)
- Analysts prefer Big Pharma over Big Biotech for 2008 (at CNNMoney.com)
- Pfizer Receives Approvable Letter from FDA for Dalbavancin (Business Wire)
- Midday Leaders & Laggards: DJIA (AP)
- UPDATE - KKR to buy Northgate Info for $1.2 bln (at Reuters)
- UPDATE - KKR says to buy Northgate for 593 mln stg (at Reuters)
- [$$] Novartis Biogen (It Does, Sort Of) (at The Wall Street Journal Online)
- Pfizer Is Sued Over Lipitor Marketing (at The Wall Street Journal Online)
- Sneak Peek 2008: Drugs & Biotechnology (at Forbes.com)
- Save Yourself From Massive Losses (at Motley Fool)
- 2007: The Year Pharma Fell in Love With Biologics (at Motley Fool)
- Novartis Hearts Biogen Idec (Sort of) (at The Wall Street Journal Online)
- A Jug of Wine, a Loaf of Bread and Lipitor (at The Wall Street Journal Online)
This Week's Barron's Roundup (at TheStreet.com)
Is Your Portfolio Safe? (at Motley Fool)
[$$] Power Players (at Barron's Online)
Exelon and FirstEnergy power up their payouts; 10% hikes from Pfizer and Lilly....
[$$] Time to Let the Dogs Out (at Barron's Online)
Dow Dogs, big and small -- and new ways to buy 'em....
UPDATE - Pfizer says US FDA wants more data on antibiotic (at Reuters)...
Flamel Wheeling and Dealing (at Motley Fool)...
Trial and Error for Array BioPharma (at Motley Fool)...
FDA Asks for More Data on Pfizer Drug (AP)
U.S. drug maker Pfizer Inc. said Friday the Food and Drug Administration requested additional data on the company's skin infection antibiotic dalbavancin....
Analysts prefer Big Pharma over Big Biotech for 2008 (at CNNMoney.com)...
Pfizer Receives Approvable Letter from FDA for Dalbavancin (Business Wire)
NEW YORK----Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration issued for dalbavancin HCl, Pfizer's once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus ....
Midday Leaders & Laggards: DJIA (AP)
Shares of AT&T Inc. made the largest midday gain on the Dow Jones industrial average Friday, as the blue chip index rallied along with the rest of the market....
UPDATE - KKR to buy Northgate Info for $1.2 bln (at Reuters)...
UPDATE - KKR says to buy Northgate for 593 mln stg (at Reuters)...
[$$] Novartis Biogen (It Does, Sort Of) (at The Wall Street Journal Online)...
Pfizer Is Sued Over Lipitor Marketing (at The Wall Street Journal Online)...
Sneak Peek 2008: Drugs & Biotechnology (at Forbes.com)...
Save Yourself From Massive Losses (at Motley Fool)...
2007: The Year Pharma Fell in Love With Biologics (at Motley Fool)...
Novartis Hearts Biogen Idec (Sort of) (at The Wall Street Journal Online)...
A Jug of Wine, a Loaf of Bread and Lipitor (at The Wall Street Journal Online)... |
